Claims for Patent: 7,176,220

Summary for Patent: 7,176,220

Title:	4-oxoquinoline compound and use thereof as pharmaceutical agent
Abstract:	An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.
Inventor(s):	Motohide Satoh, Hiroshi Kawakami, Yoshiharu Itoh, Hisashi Shinkai, Takahisa Motomura, Hisateru Aramaki, Yuji Matsuzaki, Wataru Watanabe, Shuichi Wamaki
Assignee:	Japan Tobacco Inc
Application Number:	US10/492,833
Patent Claims:	1. A method for the treatment of an HIV infection comprising: administering to a mammal in need thereof a therapeutically effective amount of a compound of formula [I], or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof: wherein, ring Cy is a C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the following group A or a heterocyclic group optionally substituted by 1 to 5 substituents selected from the following group A, wherein the heterocyclic group is a saturated or unsaturated ring containing, besides carbon atom(s), at least one heteroatom selected from a nitrogen atom, an oxygen atom, and a sulfur atom, group A is a group consisting of cyano group, phenyl group, nitro group, halogen atom, C1-4 alkyl group, halo C1-4 alkyl group, halo C1-4 alkyloxy group, —ORa1, —SRa1, —NRa1Ra2, —CONRa1Ra2, —SO2NRa1Ra2, —CORa3, —NRa1CORa3, —SO2Ra3, —NRa1SO2Ra3, —COORa1, and —NRa2COORa3, wherein Ra1 and Ra2 are the same or different and each is hydrogen atom, C1-4 alkyl group or benzyl group and Ra3 is C1-4 alkyl group; R1 is a substituent selected from the following group B or a C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atoms and the following group B, wherein group B is a group consisting of C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, —ORa4, —SRa4, —NRa4Ra5, —CONRa4Ra5, —SO2NRa4Ra5, —CORa6, —NRa4CORa6, —SO2Ra6, —NRa4SO2Ra6, —COORa4, and —NRa5COORa6, wherein Ra4 and Ra5 are the same or different and each is selected from a hydrogen atom, C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, and Ra6 is selected from a C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A; R2 is selected from a hydrogen atom or a C1-4 alkyl group; R31 is selected from a hydrogen atom, a cyano group, a hydroxy group, an amino group, a nitro group, a halogen atom, a C1-4 alkyl group, a C1-4 alkoxy group, a C1-4 alkylsulfanyl group, a halo C1-4 alkyl group, or a halo C1-4 alkyloxy group; X is selected from a C—R32 or a nitrogen atom; and Y is selected from a C—R33 or a nitrogen atom, wherein R32 and R33 are the same or different and each is selected from a hydrogen atom, cyano group, nitro group, halogen atom, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or, C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and the above-mentioned group B, —ORa7, —SRa7, —NRa7Ra8, —NRa7CORa9, —COORa10, or —N═CH—NRa10Ra11, wherein Ra7 and Ra8 are the same or different and each is selected from a hydrogen atom, group B, or C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and the above-mentioned group B, Ra9 is selected from C1-4 alkyl group, and Ra10 and Ra11 are the same or different and each is selected from a hydrogen atom or C1-4 alkyl group. 2. The method of claim 1, wherein X is C—R32 and Y is C—R33. 3. The method of claim 1, wherein ring Cy is wherein R4 and R6 are the same or different and each is a substituent selected from the following group A, wherein group A is a group consisting of cyano group, phenyl group, nitro group, halogen atom, C1-4 alkyl group, halo C1-4 alkyl group, halo C1-4 alkyloxy group, —ORa1, —NRa1, —NRa1Ra2, —CONRa1Ra2, —SO2NRa1Ra2, —CORa3, —NRa1CORa3, —SO2Ra3, —NRa1SO2Ra3, —COORa1, and —NRa2COORa3, wherein Ra1 and Ra2 are the same or different and each is selected from a hydrogen atom, C1-4 alkyl group, or benzyl group, and Ra3 is C1-4 alkyl group; R5 is a substituent selected from hydrogen atom and group A, and R4 and R5 may form a fused ring together with a benzene ring they substitute; and m is 0 or an integer of 1 to 3, and when m is 2 or 3, then R6 of each m may be the same or different. 4. The method of claim 1, wherein R2 is a hydrogen atom. 5. A compound of formula [II] or a solvate thereof or a stereolsomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof: wherein R4 and R6 are the same or different and each is a substituent selected from the following group A, wherein group A is a group consisting of cyano group, phenyl group, nitro group, halogen atom, C1-4 alkyl group, halo C1-4 alkyl group, halo C1-4 alkyloxy group, —ORa1, —SRa1, —NRa1Ra2, —CONRa1Ra2, —SO2NRa1Ra2, —CORa3, —NRa1CORa3, —SO2Ra3, —NRa1SO2Ra3, —COORa1, and —NRa2COORa3, wherein Ra1 and Ra2 are the same or different and each is selected from a hydrogen atom, C1-4 alkyl group, or benzyl group, and Ra3 is C1-4 alkyl group; R5 is a substituent selected from hydrogen atom and the above-mentioned group A, and R4 and R5 may form a fused ring together with a benzene ring they substitute; m is 0 or an integer of 1 to 3, and when m is 2 or 3, then R6 of each m may be the same or different; R1 is a substituent selected from the following group B or a C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and the following group B, wherein group B is a group consisting of C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, heterocyclic group (wherein the heterocyclic group is a saturated or unsaturated ring containing, besides carbon atom(s), at least one heteroatom selected from a nitrogen atom, an oxygen atom, and a sulfur atom as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, —ORa4, —SRa4, —NRa4Ra5 —CONRa4Ra5, —SO2NRa4Ra5, —CORa6, —NRa4CORa6, —SO2Ra6, —NRa4SO2Ra6, —COORa4, and —NRa5COORa6, wherein Ra4 and Ra5 are the same or different and each is selected from a hydrogen atom, C1-4 alkyl group, C1-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, and Ra6 is selected from C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A; R31 is selected from a hydrogen atom, a cyano group, a hydroxy group, an amino group, a nitro group, a halogen atom, a C1-4 alkyl group, a C1-4 alkoxy group, a C1-4 alkylsulfanyl group, a halo C1-4 alkyl group, or a halo C1-4 alkyloxy group; and R32 and R33 are the same or different and each is selected from a hydrogen atom, a cyano group, a nitro group, a halogen atom, a C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, a heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and the above-mentioned group B, ORa7, —SRa7, —NRa7Ra8, —NRa7CORa9, —COORa10, or —N═CH—NRa10Ra11, wherein Ra7 and Ra8 are the same or different and each is selected from a hydrogen atom, group B or C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and the above-mentioned group B, Ra9 is C1-4 alkyl group, and Ra10 and Ra11 are the same or different and each is selected from a hydrogen atom or C1-4 alkyl group. 6. The compound of claim 5, wherein R31 is selected from a hydrogen atom, a cyano group, a hydroxy group, or a C1-4 alkoxy group, or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 7. The compound of claim 6, wherein R31 is selected from a hydrogen atom, or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 8. The compound of claim 5, wherein R32 and R33 are the same or different and each is selected from a hydrogen atom, a cyano group, a halogen atom, a heterocyclic group optionally substituted by 1 to 5 substituents selected from the following group A, wherein the heterocyclic group is a saturated or unsaturated ring containing, besides carbon atom(s), at least one heteroatom selected from a nitrogen atom, an oxygen atom and a sulfur atom, and group A is a group consisting of cyano group, phenyl group, nitro group, halogen atom, C1-4 alkyl group, halo C1-4 alkyl group, halo C1-4 alkyloxy group, —ORa1, —SRa1, —NRa1Ra2, —CONRa1Ra2, —SO2NRa1Ra2, —CORa3, —NRa1CORa3, —SO2Ra3, —NRa1SO2Ra3, —COORa1, and —NRa2COORa3, wherein Ra1 and Ra2 are the same or different and each is hydrogen atom, C1-4 alkyl group, or benzyl group, and Ra3 is C1-4 alkyl group, a C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and the following group B, wherein group B is a group consisting of C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, —ORa4, —SRa4, —NRa4Ra5, —CONRa4Ra5, —SO2NRa4Ra5, —CORa6, —NRa4CORa6, —SO2Ra6, —NRa4SO2Ra6, —COORa4, and —NRa5COORa6, wherein Ra4 and Ra5 are the same or different and each is selected from a hydrogen atom, C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, and Ra6 is selected from C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, —ORa7, —SRa7, —NRa7Ra8, —NRa7CORa9, —COORa10, or —N═CH—NRa10Ra11, wherein Ra7 and Ra8 are the same or different and each is selected from a hydrogen atom, group B, or C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and the above-mentioned group B, Ra9 is C1-4 alkyl group, and Ra10 and Ra11 are the same or different and each is selected from a hydrogen atom or C1-4 alkyl group, or a solvate thereof or a stereolsomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 9. The compound of claim 5, wherein R32 is selected from a hydrogen atom, a cyano group, a halogen atom, a C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and the following group B, wherein group B is a group consisting of C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, heterocyclic group (wherein the heterocyclic group is a saturated or unsaturated ring containing, besides carbon atom(s), at least one heteroatom selected from a nitrogen atom, an oxygen atom, and a sulfur atom) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, —ORa4, —SRa4, —NRa4Ra5, —CONRa4Ra5, —SO2NRa4Ra5, —CORa6, —NRa4CORa6, —SO2Ra6, —NRa4SO2Ra6, —COORa4, and —NRa5COORa6, wherein Ra4 and Ra5 are the same or different and each is selected from a hydrogen atom, C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, and Ra6 is selected from C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, —ORa7, —SRa7, —NRa7Ra8, —NRa7CORa9, or —COORa10, wherein Ra7 and Ra8 are the same or different and each is selected from a hydrogen atom, group B, or C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and the above-mentioned group B, Ra9 is C1-4 alkyl group, and Ra10 is selected from a hydrogen atom or C1-4 alkyl group, or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 10. The compound of claim 9, wherein R32 is selected from a hydrogen atom, —ORa7, or —NRa7Ra8, wherein Ra7 and Ra8 are the same or different and each is selected from a hydrogen atom, group B, or C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and the above-mentioned group B, or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 11. The compound of claim 8, wherein R33 is selected from a hydrogen atom, a C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and the following group B, wherein group B is a group consisting of C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, heterocyclic group (wherein the heterocyclic group is a saturated or unsaturated ring containing, besides carbon atom(s), at least one heteroatom selected from a nitrogen atom, an oxygen atom, and a sulfur atom) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, —ORa4, —SRa4, —NRa4Ra5, —CONRa4Ra5, —SO2NRa4Ra5, —CORa6, —NRa4CORa6, —SO2Ra6, —NRa4SO2Ra6, —COORa4, and —NRa5COORa6, wherein Ra4 and Ra5 are the same or different and each is selected from a hydrogen atom, C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, and Ra6 is selected from C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, —ORa7, or —NRa7Ra8 wherein Ra7 and Ra8 are the same or different and each is selected from a hydrogen atom, group B, or C1-10 alkyl group, optionally substituted by 1 to 3 substituents selected from halogen atom and the above-mentioned group B, or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 12. The compound of claim 11, wherein R33 is selected from a hydrogen atom, —ORa7, or —NRa7Ra8, wherein Ra7 and Ra8 are the same or different and each is selected from a hydrogen atom, group B or C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and the above-mentioned group B, or a solvate thereof or a stereolsomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 13. The compound of claim 5, wherein Ra7 and Ra8 are the same or different and each is selected from a C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and the following group B, wherein group B is a group consisting of C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, heterocyclic group (wherein the heterocyclic group is a saturated or unsaturated ring containing, besides carbon atom(s), at least one heteroatom selected from a nitrogen atom, an oxygen atom and a sulfur atom) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, —ORa4, —SRa4, —NRa4Ra5, —CONRa4Ra5, —SO2NRa4Ra5, —CORa6, —NRa4CORa6, —SO2Ra6, —NRa4SO2Ra6, —COORa4, and —NRa5COORa6, wherein Ra4 and Ra5 are the same or different and each is selected from a hydrogen atom, C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, and Ra6 is selected from C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 14. The compound of claim 5, wherein R4 and R5 are the same or different and each is a substituent selected from cyano group, phenyl group, nitro group, halogen atom, C1-4 alkyl group, halo C1-4 alkyl group, halo C1-4 alkyloxy group, —ORa1, —SRa1, —NRa1Ra2, —CONRa1Ra2, —SO2NRa1Ra2, —NRa1CORa3, —SO2Ra3, —NRa2COORa3, and —COORa1, wherein Ra1 and Ra2 are the same or different and each is hydrogen atom, C1-4 alkyl group, or benzyl group, and Ra3 is C1-4 alkyl group, or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 15. The compound of claim 14, wherein R4 is selected from a phenyl group, a halogen atom, a C1-4 alkyl group, a halo C1-4 alkyloxy group, —ORa1, —NRa1Ra2, —CONRa1Ra2, —SO2NRa1Ra2, —NRa1CORa3, —SO2Ra3, —NRa1SO2Ra3, or —COORa1, wherein Ra1 and Ra2 are the same or different and each is selected from a hydrogen atom, C1-4 alkyl group or benzyl group, and Ra3 is C1-4 alkyl group, or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 16. The compound of claim 15, wherein R4 is a halogen atom, or a solvate thereof or a stereolsomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 17. The compound of claim 5, wherein R5 is selected from a hydrogen atom, a cyano group, a phenyl group, a nitro group, a halogen atom, a C1-4 alkyl group, a halo C1-4 alkyl group, —ORa1, —SRa1, —NRa1Ra2, —CONRa1Ra2, —SO2NRa1Ra2, or —NRa1CORa3, wherein Ra1 and Ra2 are the same or different and each is selected from a hydrogen atom, C1-4 alkyl group, or benzyl group, and Ra3 is C1-4 alkyl group, or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 18. The compound of claim 5, wherein R6 is a halogen atom, or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 19. The compound of claim 5, wherein m is 0 or 1, or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 20. The compound of claim 5, wherein R1 is selected from a C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the following group A, wherein group A is a group consisting of cyano group, phenyl group, nitro group, halogen atom, C1-4 alkyl group, halo C1-4 alkyl group, halo C1-4 alkyloxy group, —ORa1, —SRa1, —NRa1Ra2, —CONRa1Ra2, —SO2NRa1Ra2, —CORa3, —NRa1CORa3, —SO2Ra3, —NRa1SO2Ra3, —COORa1, and —NRa2COORa3, wherein Ra1 and Ra2 are the same or different and each is selected from a hydrogen atom, C1-4 alkyl group, or benzyl group, and Ra3 is C1-4 alkyl group, a substituent selected from —NRa4Ra5, —NRa4CORa6, —NRa4SO2Ra6, and —NRa5COORa6, wherein Ra4 and Ra5 are the same or different and each is selected from a hydrogen atom, C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or heterocyclic group (wherein the heterocyclic group is a saturated or unsaturated ring containing, besides carbon atom(s), at least one heteroatom selected from a nitrogen atom, an oxygen atom, and a sulfur atom) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, and Ra6 is selected from C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or a C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and group B, wherein group B is a group consisting of C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, —ORa4, —SRa4, —NRa4Ra5, —CONRa4Ra5, —SO2NRa4Ra5, —CORa6, —NRa4CORa6, —SO2Ra6, —NRa4SO2Ra6, —COORa4, and —NRa5COORa6 (wherein Ra4, Ra5, Ra6, and group A are as defined above), or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 21. The compound of claim 20, wherein R1 is a C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and group B, wherein group B is a group consisting of C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, —ORa4, —SRa4, —NRa4Ra5, —CONRa4Ra5, —SO2NRa4Ra5, —CORa6, —NRa4CORa6, —SO2Ra6, —NRa4SO2Ra6, —COORa4, and —NRa5COORa6, wherein Ra4 and Ra5 are the same or different and each is selected from a hydrogen atom, C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, and Ra6 is selected from C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 22. A method for the treatment of an HIV infection, comprising: administering to a mammal in need thereof a therapeutically effective amount of a compound of formula (III) or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof: wherein ring Cy is a C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the following group A or a heterocyclic group optionally substituted by 1 to 5 substituents selected from the following group A, wherein the heterocyclic group is a saturated or unsaturated ring containing, besides carbon atom(s), at least one heteroatom selected from a nitrogen atom, an oxygen atom and a sulfur atom, group A is a group consisting of cyano group, phenyl group, nitro group, halogen atom, C1-4 alkyl group, halo C1-4 alkyl group, halo C1-4 alkyloxy group, —ORa1, —SRa1, —NRa1Ra2, —CONRa1Ra2, —SO2NRa1Ra2, —CORa3, —NRa1CORa3, —SO2Ra3, —NRa1SO2Ra3, —COORa1, and —NRa2COORa3, wherein Ra1 and Ra2 are the same or different and each is selected from a hydrogen atom or C1-4 alkyl group, and Ra3 is C1-4 alkyl group; R1 is a substituent selected from the following group B or a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from halogen atom and the following group B, wherein group B is a group consisting of C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, —ORa4, —SRa4, —NRa4Ra5, —CONRa4Ra5, —SO2NRa4Ra5, —CORa6, —NRa4CORa6, —SO 2Ra6, —NRa4SO2Ra6, —COORa4, and —NRa5COORa6, wherein Ra4 and Ra5 are the same or different and each is selected from a hydrogen atom, C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, and Ra6 is selected from C1-4 alkyl group, C3-10 carbon ring group optionally substituted by 1 to 5 substituents selected from the above-mentioned group A, or heterocyclic group (as defined above) optionally substituted by 1 to 5 substituents selected from the above-mentioned group A; R2 is selected from a hydrogen atom or a C1-4 alkyl group; R3 is selected from a cyano group, a hydroxy group, an amino group, a nitro group, a halogen atom, a C1-4 alkyl group, a C1-4 alkoxy group, a C1-4 alkylsulfanyl group, a halo C1-4 alkyl group, or a halo C1-4 alkyloxy group; n is selected from 0 or an integer of 1 to 3 and when n is 2 or 3, R3 each may be the same or different. 23. A pharmaceutical composition comprising a compound according to claim 5, or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 24. A method for the treatment of an HIV infection, which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound according to claim 5, or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 25. The method according to claim 24, wherein the compound is administered at a dosage ranging from 0.01 mg to 1 g per administration for an adult. 26. The method according to claim 24, wherein the compound is administered at a dosage for inhibiting activity specific for HIV integrase. 27. A method for inhibiting HIV integrase, comprising administering to a mammal in need thereof an HIV integrase inhibiting effective amount of a compound according to claim 5 or a solvate thereof or a stereoisomer thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 28. A method for the treatment of an HIV infection, comprising: administering to a mammal in need thereof a composition comprising a therapeutically effective amount of a compound of the formula: or a solvate thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 29. A method for inhibiting HIV integrase, comprising: administering to a mammal in need thereof a composition comprising an HIV integrase inhibiting effective amount of a compound of the formula: or a solvate thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 30. A compound of the formula: or a solvate thereof or a tautomer thereof or a pharmaceutically acceptable salt thereof. 31. The method according to any one of claims 1, 22, 24, 27, 28 or 29 wherein the mammal is a human.